JPRN-UMIN000010787已完成4 期
Effects of the combination therapy of irbesartan and indapamide in chronik kidney disease with hypertension - Irbesatran and indapamide in chronick kidney disease
Division of Nephrology, Department of Internal medicine, Jichi Medical University0 个研究点目标入组 30 人开始时间: 2013年5月23日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)chronik kidney disease udergoing hemodialysis or peritoneal dialysis 2)acute kindey injury 3)severe heart failure 4)type I or type II diabetes mellitus with poor glucose control (serum glycosylated hemoglobin [HbA1c] level > 9%) 5)severe liver dysfunction 6)hyperkalemia (> 5.5 mEq/ml) 7)pregnant women 8)patinets who will not give informed concent
研究者
相似试验
招募中
不适用
Effect of on combination therapy with irbesartan and amlodipine besilate on clinical blood pressure, home blood pressure and blood pressure variability in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD G1-G4)JPRN-UMIN000013213Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine30
进行中（未招募）
不适用
Irbesartan versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Hypertensive Albuminuria in Subjects at Elevated Cardiovascular Risk - IMPROVEEUCTR2004-000022-75-LVBristol-Myers Squibb International Corporation615
进行中（未招募）
不适用
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk - IMPROVEAlbuminuria in hypertensive subjects at increased cardiovascular risk.EUCTR2004-000022-75-LTBristol-Myers Squibb International Corporation615
进行中（未招募）
1 期
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Subjects at Elevated Cardiovascular Risk - IMPROVEEUCTR2004-000022-75-ESBristol-Myers Squibb International Corporation615
进行中（未招募）
不适用
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk.EUCTR2004-000022-75-ITBRISTOL-M.SQUIBB600